35166-78-0 Usage
Description
CYCLOHEXYLMETHYLMAGNESIUM BROMIDE is an organomagnesium compound that serves as a key reactant in various organic synthesis processes. It is known for its ability to facilitate isomerization polymerization of alkenylcyclohexanes, intramolecular rearrangements of vinylidenecyclopropanes, and cycloisomerization of cyclic and acyclic enynes. Additionally, it plays a crucial role in the synthesis of biologically active molecules, making it a valuable reagent in the field of organic chemistry.
Uses
Used in Polymer Synthesis:
CYCLOHEXYLMETHYLMAGNESIUM BROMIDE is used as a reactant in the isomerization polymerization of alkenylcyclohexanes, enabling the formation of polymers with unique properties and potential applications in various industries.
Used in Intramolecular Rearrangements:
In the intramolecular rearrangements of vinylidenecyclopropanes, CYCLOHEXYLMETHYLMAGNESIUM BROMIDE acts as a reactant, facilitating the formation of new molecular structures with potential applications in pharmaceutical and chemical industries.
Used in Cycloisomerization Reactions:
CYCLOHEXYLMETHYLMAGNESIUM BROMIDE is used as a reactant in the cycloisomerization of cyclic and acyclic enynes, leading to the synthesis of complex organic molecules with potential applications in various fields.
Used in Pharmaceutical Synthesis:
CYCLOHEXYLMETHYLMAGNESIUM BROMIDE is used as a reactant in the synthesis of biologically active molecules, such as dipeptidyl boronic acid proteasome inhibitors, which have potential applications in the development of new drugs for various diseases.
Used in Antitumor Agents:
In the synthesis of substituted 1,3-dihydroindole-2-ones with antitumor effects, CYCLOHEXYLMETHYLMAGNESIUM BROMIDE serves as a reactant, contributing to the development of new cancer treatments.
Used in Enzyme Inhibitors:
CYCLOHEXYLMETHYLMAGNESIUM BROMIDE is used as a reactant in the synthesis of sulfur-free transition state nucleoside analog inhibitors of methylthioadenosine nucleosidase and phosphorylase, which have potential applications in the development of new therapeutic agents for various diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 35166-78-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,5,1,6 and 6 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 35166-78:
(7*3)+(6*5)+(5*1)+(4*6)+(3*6)+(2*7)+(1*8)=120
120 % 10 = 0
So 35166-78-0 is a valid CAS Registry Number.
InChI:InChI=1/C7H13.BrH.Mg/c1-7-5-3-2-4-6-7;;/h7H,1-6H2;1H;/q;;+1/p-1/rC7H13BrMg/c8-9-6-7-4-2-1-3-5-7/h7H,1-6H2
35166-78-0Relevant articles and documents
SYNTHESIS METHOD FOR L-CYCLIC ALKYL AMINO ACID AND PHARMACEUTICAL COMPOSITION HAVING THEREOF
-
Paragraph 0084, (2016/11/17)
A synthesis method for L-cyclic alkyl amino acid and a pharmaceutical composition having the said amino acid are provide in the present disclosure provides. The synthesis method comprises: step A.) preparing a cyclic alkyl keto acid or a cyclic alkyl keto acid salt having Structural Formula (I) or Structural Formula (II), and step B.) mixing the cyclic alkyl keto acid or the cyclic alkyl keto acid salt with ammonium formate, a leucine dehydrogenase, a formate dehydrogenase and a coenzyme NAD+, and carrying out a reductive amination reaction to generate the L-cyclic alkyl amino acid, wherein the Structural Formula (I) is where n1≧1, m1≧0 and the M1 is H or a monovalent cation; the Structural Formula (II) is where n2≧0, m2≧0, the M2 is H or a monovalent cation, an amino acid sequence of the leucine dehydrogenase is SEQ ID No.1.
GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES
-
Page/Page column 54, (2010/02/15)
The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.
